30 Day Trial
ORTHOKNOW logo

ORTHOKNOW content is posted to these pages in real time.

Monthly compilations are available in PDF form.

Quarterly Review

3Q13 Revenue: Stryker

$2,151MM, +7% (U.S. $1,449MM, +7%, ex-U.S. $702MM, +8%)


Reconstructive $949MM, +9% (U.S. +10%, ex-U.S. +8%)

  • Hips $304MM, +9% (U.S. +9%, ex-U.S. +9%)
  • Knees $315MM, +2% (U.S. +4%, ex-U.S. -1%)
  • Trauma/Extremities $277MM, +20% (U.S. +23%, ex-U.S. +18%)


MedSurg Equipment $792MM, +3% (U.S. +3%, ex-U.S. +2%)

  • Endoscopy $279MM, +8% (U.S. +11%, ex-U.S. +3%)


Neurotechnology/Spine $410MM, +10% (U.S. +8%, ex-U.S. +13%)

  • Spine $183MM, +6% (U.S. +3%, ex-U.S. +13%)
  • Neurotechnology $227MM, +14% (U.S. +14%, ex-U.S. +14%)

MedSurg includes patient handling and emergency medical equipment.

 

  • 7 consecutive quarters of double-digit trauma growth, including 39% increase in foot/ankle in 3Q
  • Trauma sales led by new products, sales execution
  • Knees still constrained by absence of ShapeMatch guides, distributor transition in Asia affecting smaller countries in region
  • Knee volume improved substantially in 3Q over 1H13
  • Will continue direct-to-consumer knee campaign into 2014, with changes to media mix
  • ES2 percutaneous pedicle screw and differentiated interbody technology offering strong growth in spine
  • MAKO Surgical acquisition: more clarity to come, but claims about 1-2 years to transition Stryker  uni knee and total hip products to RIO platform
  • Not seeing the challenge of low-cost generic manufacturing competition noted by peers
  • No significant headwinds from competitive knee launches